H.C. Wainwright analyst Raghuram Selvaraju downgraded UroGen Pharma (URGN) to Neutral from Buy without a price target The UGN-102 negative FDA panel vote means the firm now expects a rejection next month. The negative panel vote makes it difficult to envisage a timely approval of UGN-102, the analyst tells investors in a research note. H.C. Wainwright cites the “current uncertainties” for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: